Cancer Research Annual Meeting 2010 Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, S.-M.
Right arrow Articles by Harari, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, S.-M.
Right arrow Articles by Harari, P. M.
[Cancer Research 62, 4300-4306, August 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa)1

Shyh-Min Huang, Jing Li, Eric A. Armstrong and Paul M. Harari2

Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792

ZD1839 ("Iressa") is an orally-active, selective epidermal growth factor receptor-tyrosinekinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with radiation in human squamous cell carcinomas (SCCs) of the head and neck. ZD1839 produced a dose-dependent inhibition of cellular proliferation in human SCCs grown in culture. Flow cytometry analysis of cell cycle progression confirmed the accumulation of cells in G1 phase after exposure to ZD1839. Clonogenic analysis demonstrated that treatment of SCCs with ZD1839 reduced cell survival after radiation exposure. Flow cytometric analysis further demonstrated that treatment of SCCs with ZD1839 amplified radiation-induced apoptosis. Tumor xenograft studies confirmed that oral administration of ZD1839, or focal radiation, resulted in partial and transient tumor regression in both SCC-1 and SCC-6 xenografts. In contrast, profound tumor regression and regrowth delay was observed in mice treated with the combination of ZD1839 and radiation. To examine antiangiogenic effects, we studied the impact of ZD1839 on human umbilical vascular endothelial cells (HUVECs). In the presence of reconstituted Matrigel matrix, HUVECs established a capillary-like network structure (tube formation). Treatment with ZD1839 reduced the cell-to-cell interaction of HUVECs, resulting in disruption of tube formation. The effect of ZD1839 was further examined using an in vivo tumor xenograft model of angiogenesis (Matrigel plug) in athymic mice. Systemic treatment with ZD1839 significantly inhibited tumor-induced neovascularization across the Matrigel plug. Taken together, these results suggest that the antitumor activity of ZD1839 in combination with radiation appears to derive from not only proliferative growth inhibition (with associated cell cycle arrest and enhancement of radiation-induced apoptosis) but also from inhibition of tumor angiogenesis.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
S. YABUUCHI, Y. KATAYOSE, A. ODA, M. MIZUMA, S. SHIRASOU, T. SASAKI, K. YAMAMOTO, M. OIKAWA, T. RIKIYAMA, T. ONOGAWA, et al.
ZD1839 (IRESSA(R)) Stabilizes p27Kip1 and Enhances Radiosensitivity in Cholangiocarcinoma Cell Lines
Anticancer Res, April 1, 2009; 29(4): 1169 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, and P. M. Harari
Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells
Clin. Cancer Res., March 1, 2009; 15(5): 1585 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev
Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn
Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity
Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-H. Gow, C.-R. Chien, Y.-L. Chang, Y.-H. Chiu, S.-H. Kuo, J.-Y. Shih, Y.-C. Chang, C.-J. Yu, C.-H. Yang, and P.-C. Yang
Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response
Clin. Cancer Res., January 1, 2008; 14(1): 162 - 168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Mitra
In Reply
J. Clin. Oncol., October 10, 2007; 25(29): 4698 - 4699.
[Full Text] [PDF]

Home page
 JCOHome page
P. M. Harari, G. W. Allen, and J. A. Bonner
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Erjala, M. Sundvall, T. T. Junttila, N. Zhang, M. Savisalo, P. Mali, J. Kulmala, J. Pulkkinen, R. Grenman, and K. Elenius
Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells.
Clin. Cancer Res., July 1, 2006; 12(13): 4103 - 4111.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Mitra and R. Simcock
Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field
J. Clin. Oncol., June 1, 2006; 24(16): e28 - e29.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity
EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms.
Cancer Res., March 15, 2006; 66(6): 3197 - 3204.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. J. Friedmann, M. Caplin, B. Savic, T. Shah, C. J. Lord, A. Ashworth, J. A. Hartley, and D. Hochhauser
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Mol. Cancer Ther., February 1, 2006; 5(2): 209 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. T. Lee, A. J. Mountain, M. P. Kelly, C. Hall, A. Rigopoulos, T. G. Johns, F. E. Smyth, M. W. Brechbiel, E. C. Nice, A. W. Burgess, et al.
Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478
Clin. Cancer Res., October 1, 2005; 11(19): 7080s - 7086s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Langer and M. P. Mehta
Current Management of Brain Metastases, With a Focus on Systemic Options
J. Clin. Oncol., September 1, 2005; 23(25): 6207 - 6219.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I.-A. Kim, S.-S. Bae, A. Fernandes, J. Wu, R. J. Muschel, W. G. McKenna, M. J. Birnbaum, and E. J. Bernhard
Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines
Cancer Res., September 1, 2005; 65(17): 7902 - 7910.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Bentzen, B. M. Atasoy, F. M. Daley, S. Dische, P. I. Richman, M. I. Saunders, K. R. Trott, and G. D. Wilson
Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial
J. Clin. Oncol., August 20, 2005; 23(24): 5560 - 5567.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, A. M. Chinnaiyan, and P. M. Harari
Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva)
Cancer Res., April 15, 2005; 65(8): 3328 - 3335.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
T. D. Chung and W. C. Broaddus
Molecular Targeting in Radiotherapy: Epidermal Growth Factor Receptor
Mol. Interv., February 1, 2005; 5(1): 15 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge
ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity
Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser
Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839)
Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. F. McCarty, J. Wey, O. Stoeltzing, W. Liu, F. Fan, C. Bucana, P. F. Mansfield, A. J. Ryan, and L. M. Ellis
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer
Mol. Cancer Ther., September 1, 2004; 3(9): 1041 - 1048.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Raben, C. Bianco, V. Damiano, R. Bianco, D. Melisi, C. Mignogna, F. P. D'Armiento, L. Cionini, A. R. Bianco, G. Tortora, et al.
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
Mol. Cancer Ther., August 1, 2004; 3(8): 977 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Dominguez-Escrig, J. D. Kelly, D. E. Neal, S. M. King, and B. R. Davies
Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4874 - 4884.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano
Pharmacological background of EGFR targeting
Ann. Onc., July 1, 2004; 15(7): 1007 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients
Ann. Onc., May 1, 2004; 15(5): 786 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Harari and S.-M. Huang
Searching for Reliable Epidermal Growth Factor Receptor Response Predictors: Commentary re M. K. Nyati et al., Radiosensitization by Pan-ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clin. Cancer Res., 10: 691-700, 2004.
Clin. Cancer Res., January 15, 2004; 10(2): 428 - 432.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Li, C.-M. Chang, M. Yuan, W. G. McKenna, and H.-K. G. Shu
Resistance to Small Molecule Inhibitors of Epidermal Growth Factor Receptor in Malignant Gliomas
Cancer Res., November 1, 2003; 63(21): 7443 - 7450.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Liang, Y. Lu, W. Jin, K. K. Ang, L. Milas, and Z. Fan
Sensitization of breast cancer cells to radiation by trastuzumab
Mol. Cancer Ther., November 1, 2003; 2(11): 1113 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q.-T. Le and A. J. Giaccia
Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Tofilon, S. Saxman, and C. N. Coleman
Molecular Targets for Radiation Therapy: Bringing Preclinical Data into Clinical Trials
Clin. Cancer Res., September 1, 2003; 9(10): 3518 - 3520.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. She, F. Lee, J. Chen, A. Haimovitz-Friedman, V. A. Miller, V. R. Rusch, M. G. Kris, and F. M. Sirotnak
The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice, with a Marked Improvement in Therapeutic Index
Clin. Cancer Res., September 1, 2003; 9(10): 3773 - 3778.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wachsberger, R. Burd, and A. P. Dicker
Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction
Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone
Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways
Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron
Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy
Cancer Res., March 1, 2003; 63(5): 1012 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn
Targeting the Epidermal Growth Factor Receptor for Cancer Therapy
J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.